Anixa Biosciences (ANIX) to Release Earnings on Tuesday

Anixa Biosciences (NASDAQ:ANIX) is expected to announce its Q1 2026 results before the market opens on Tuesday, March 10th. Analysts expect Anixa Biosciences to post earnings of ($0.09) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, March 13, 2026 at 4:00 PM ET.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Monday, January 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09).

Anixa Biosciences Trading Down 0.7%

Shares of ANIX stock opened at $2.96 on Tuesday. Anixa Biosciences has a 1-year low of $2.33 and a 1-year high of $5.46. The company has a market capitalization of $98.80 million, a price-to-earnings ratio of -8.46 and a beta of 0.48. The stock’s fifty day simple moving average is $3.08 and its 200-day simple moving average is $3.56.

Insiders Place Their Bets

In other Anixa Biosciences news, Director Arnold M. Baskies bought 10,000 shares of Anixa Biosciences stock in a transaction on Wednesday, January 28th. The stock was purchased at an average cost of $3.04 per share, for a total transaction of $30,400.00. Following the completion of the purchase, the director directly owned 135,000 shares of the company’s stock, valued at $410,400. The trade was a 8.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 26.40% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

Large investors have recently bought and sold shares of the business. CIBC Private Wealth Group LLC boosted its stake in shares of Anixa Biosciences by 78.6% during the 4th quarter. CIBC Private Wealth Group LLC now owns 27,865 shares of the company’s stock worth $87,000 after acquiring an additional 12,265 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Anixa Biosciences by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock valued at $1,095,000 after acquiring an additional 7,271 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Anixa Biosciences in the 3rd quarter worth approximately $51,000. Susquehanna International Group LLP boosted its position in Anixa Biosciences by 378.4% during the third quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock worth $265,000 after purchasing an additional 63,584 shares during the period. Finally, Prosperity Wealth Management Inc. boosted its position in Anixa Biosciences by 14.5% during the third quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock worth $138,000 after purchasing an additional 5,300 shares during the period. 29.13% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ANIX has been the topic of several research analyst reports. Wall Street Zen cut Anixa Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Zacks Research cut shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anixa Biosciences in a research report on Monday, December 29th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Wednesday, February 4th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $9.00.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.